VX15 (pepinemab) Emerging Drug Insight and Market Forecast – 2032

VX15 (pepinemab) Emerging Drug Insight and Market Forecast – 2032

“VX15 (pepinemab) Emerging Drug Insight and Market Forecast – 2032” report provides comprehensive insights about VX15 (pepinemab) for Huntington’s disease in the 7MM. A detailed picture of the VX15 (pepinemab) for Huntington’s disease in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the UK, and Japan, for the study period 2019–2032 is provided in this report along with a detailed description of the VX15 (pepinemab) for Huntington’s disease. The report provides insight about mechanism of action, dosage and administration, as well as research and development activity including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the VX15 (pepinemab) market forecast, analysis for Huntington’s disease in the 7MM, descriptive analysis such as SWOT, analyst views, comprehensive overview of market competitors, and brief about other emerging therapies in Huntington’s disease.

Drug Summary

VX15/2503 (pepinemab) is a novel humanized monoclonal IgG4 antibody that binds and blocks the signaling activity of SEMA4D. SEMA4D is an extracellular signaling molecule that regulates the migration and activation of immune and inflammatory cells at sites of injury and cancer. Preclinical testing has demonstrated the beneficial effects of anti-SEMA4D treatment in a variety of neurodegenerative disease models. Vaccinex is committed to the development of this important antibody that has the potential to help people with different neurodegenerative disorders that share common mechanisms of pathology.

In chronic brain diseases, such as Huntington's, the company has discovered that SEMA4D triggers neuro-inflammation with an associated loss of normal brain functions that accelerates disease progression. Pepinemab’s mechanism of action is to block the SEMA4D signal so as to preserve normal functions and slow or prevent disease progression. In cancer, the company discovered that tumors exploit the expression of a high concentration of SEMA4D at their margins to block immune cell infiltration as one of several mechanisms to evade immune protection against cancer.

Vaccinex has completed the Phase II (NCT02481674; SIGNAL-HD) clinical trial to evaluate the effect of pepinemab in both early manifest and late prodromal patients with HD. Endpoints of the study included safety and tolerability, clinical and behavioral outcomes, as well as measures of brain volume, metabolic activity, and inflammation.

Scope of the Report

The report provides insights into:

A comprehensive product overview including the VX15 (pepinemab) description, mechanism of action, dosage and administration, research and development activities in Huntington’s disease.

Elaborated details on VX15 (pepinemab) regulatory milestones and other development activities have been provided in this report.

The report also highlights the VX15 (pepinemab) research and development activity in Huntington’s disease in detail across the United States, Europe and Japan.

The report also covers the patents information with expiry timeline around VX15 (pepinemab) (Deutetrabenazine).

The report contains forecasted sales of VX15 (pepinemab) for Huntington’s disease till 2032.

Comprehensive coverage of the late-stage emerging therapies for Huntington’s disease.

The report also features the SWOT analysis with analyst views for VX15 (pepinemab) in Huntington’s disease.

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

VX15 (pepinemab) Analytical Perspective by DelveInsight

In-depth VX15 (pepinemab) Market Assessment

This report provides a detailed market assessment of VX15 (pepinemab) in Huntington’s disease in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2025 to 2032.

VX15 (pepinemab) Clinical Assessment

The report provides the clinical trials information of VX15 (pepinemab) in Huntington’s disease covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights

In the coming years, the market scenario for Huntington’s disease is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.

The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence VX15 (pepinemab) dominance.

Other emerging products for Huntington’s disease are expected to give tough market competition to VX15 (pepinemab) and launch of late-stage emerging therapies in the near future will significantly impact the market.

A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of VX15 (pepinemab) in Huntington’s disease.

Our in-depth analysis of the forecasted sales data from 2025 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the VX15 (pepinemab) in Huntington’s disease.

Key Questions

What is the product type, route of administration and mechanism of action of VX15 (pepinemab)?

What is the clinical trial status of the study related to VX15 (pepinemab) in Huntington’s disease and study completion date?

What are the key collaborations, mergers and acquisitions, licensing and other activities related to the VX15 (pepinemab) development?

What are the key designations that have been granted to VX15 (pepinemab) for Huntington’s disease?

What is the forecasted market scenario of VX15 (pepinemab) for Huntington’s disease?

What are the forecasted sales of VX15 (pepinemab) in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?

What are the other emerging products available in Huntington’s disease and how are they giving competition to VX15 (pepinemab) for Huntington’s disease?

Which are the late-stage emerging therapies under development for the treatment of Huntington’s disease?